Key Highlights: Implications: Cipla’s licensing deal adds a potential new HER2-targeted cancer treatment to its pipeline in India, South Africa and five other emerging markets, stren...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
